Roche’s (RHHBY) experimental obesity pill CT-996 was tied to high rates of nausea and vomiting, as well as other side effects in a small study, Bloomberg’s Naomi Kresge reports. The company presented the findings late Wednesday at the European Association for the Study of Diabetes meeting in Madrid. The study lasted four weeks, and Roche had argued that gradually increasing the dose could mitigate side effects; five out of six patients who slowly took more reported nausea, while one developed chronic reflux and two had vomiting, Roche said. Other obesity drug makers include Novo Nordisk (NVO) and Eli Lilly (LLY).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Novo amycretin safety ‘not quite as clean as we’d like,’ says Deutsche Bank
- Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
- Roche integrates more than 20 advanced AI algorithms
- Poseida Therapeutics initiates P-BCMA-ALLO1 Phase 1b trial
- Roche to present data for fenebrutinib from Phase II FENopta OLE study